NCT05926960 2026-03-09
PORTSIDE
Pfizer
Phase 2 Terminated
Clinical Trials
5 trialsNCT02621021 2025-11-21
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04869137 2025-10-31
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT02302339 2019-09-06
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
Celldex Therapeutics
Phase 2 Terminated
NCT03666325 2018-09-11
I-Tackle
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown